SAN FRANCISCO, Dec. 20, 2022 (GLOBE NEWSWIRE) — Novotech, the Asia Pacific biotech specialist CRO, is proud to be a Gold Sponsor at Biotech Showcase 2023. dr John Moller, CEO of Novotech, and experts from the Novotech USA and Asia Pacific teams will attend the conference.
Meetings can be scheduled through the PartneringOne Portal.
Novotech will share the benefits of the Asia-Pacific region for accelerated clinical trials, where biotechs have access to Novotech’s large patient population, strong local regulatory knowledge, extensive site and KOL networks, and a solid reputation for data quality.
Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific, offering exclusive sponsorship benefits.
The latest industry research release from GlobalData and Novotech found that nearly 50% of new trials worldwide have sites in Asia Pacific.
According to the new publication entitled State of the Global Biotech Landscape: Where the Opportunities Lie Demand for trial sites in Asia Pacific is strong, with nearly half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific.
The data shows that nearly 12,900 of the new trials had sites in the Asia-Pacific region.
The report also found that the Asia-Pacific region, which has more than 6,772 trial centers, each with access to an average of 2,136 million people, has significant untapped capacity that represents an opportunity for multinational trials growth in the region .
Novotech was recognized this month with the 2022 Frost & Sullivan Company of the Year Award for Best Practices in the Asia Pacific CRO Industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices Awards since 2006.
Frost & Sullivan said:
“Our approach involves the use of best practices and strategic analysis across a value chain. With this in mind, Frost & Sullivan recognizes Novotech for its valuable achievement.
Novotech addresses…
[ad_2]
Source story
